Zhejiang refines rare disease treatment reimbursement



Zhejiang province’s Healthcare Security Administration (HSA) bureau released a draft proposal in relation to rare disease medical insurance, taking effect from January 1, 2020. The document covers rare disease drug accessibility and reimbursement ratios.

Zhejiang will establish a rare disease healthcare security fund, sourced from Critical Disease Insurance (CDI) funds and provincial subsidies. Local CDI funds will make an annual one-time transfer to the provincial HSA at a rate of RMB 2 (USD 0.29) per holder of basic provincial medical insurance. The fund will implement special account management and independent financial accounting.

A dynamic adjustment mechanism for rare disease drug pricing will be established according to the national rare disease list. The program will include drugs marketed in China which demonstrate clear efficacy, are in urgent demand, and are not covered by basic medical insurance or CDI schemes. Regular negotiations will follow the principle of “expert argumentation, price negotiation, and dynamic adjustment”, and consider the economic and social situation in the province, along with the balance of the fund.

Rare disease insurance reimbursement ratios are to be calculated annually, paid by installments, and will have caps on contributions. The reimbursement rates are as follows: 80% for RMB 0-300,000 (USD 0-43,000); 90% for RMB 300,000-700,000 (USD 43,000-100,000); and 100% for RMB 700,000 (USD 100,000) and above.


Reference:

Related news
According to GBI analysis, Argentina’s National Administration of Drugs, Food and Medical Technology (ANMAT) last week nodded local laboratory Elea-Phoenix’s Alcaf (carfilzomib), a first market entrant generic of Amgen’s orphan drug Kyprolis.
Three groups from Brazilian research institutions have recently posted results on their investigations on central nervous system (CNS) cancer, Chagas disease, and leishmaniasis.
Argentina’s Department of Health this week published guidelines for the diagnosis and treatment of spinal muscular atrophy (SMA).
The Center for Drug Evaluation (CDE) last Friday released two draft proposals setting out planned adjustments to the conditions for priority review status awards and introducing a new breakthrough status for innovative therapeutic drugs in China.
Argentina’s Department of Health last week incorporated long-acting contraceptives and cystic fibrosis (CF) treatments into the Compulsory Medical Plan (PMO)’s coverage, benefiting both public and private healthcare systems​.
Recent news
Zoé Robledo Aburto, head of Mexico's Social Security Institute (IMSS), last week announced that the public institution will invest MXN 13 billion (USD 676 million) in 2020 as part of a program to complete over 111 new hospitals, 132 family clinics, 120 remodelings, and 200 additional infrastructure projects by the end of 2024.
Luiz Henrique Mandetta, head of Brazil’s Ministry of Health (MoH), last week discussed the Conecte SUS project, which aims to digitalize the Unified Health System (SUS) network, allowing public and private healthcare workers to access patients' clinical records from a centralized database.
GBI analysis shows that Argentina’s National Administration of Drugs, Food and Medical Technology (ANMAT) last week approved Monte Verde’s Vilzer (vildagliptin), a first-mover generic of Novartis’ hyperglycemia treatment Galvus/Glucemix/Zomarist​.
The Latin American Association of Pharmaceutical Industries (ALIFAR) shared with The Pharma Letter its plans for the current period of economic challenges and political changes.
  • 1574154772332
  • Argentina,Brazil,Mexico,Colombia,Peru,Venezuela,Chile,Uruguay,Paraguay,Ecuador ,Costa Rica,El Salvador,Bolivia ,Guatemala,Dominican Republic
  • Policy/Regulatory, Company
China-based Maider Medical Industry Equipment Co., Ltd announced that its initial public offering (IPO) will go ahead with the release of 20.9 million shares at RMB 24.79 (USD 3.53) per share on the Shanghai Science and Technology Innovation Board (STAR).
China-based China Grand Pharmaceutical and Healthcare Holdings Ltd (CGP; HK.512) announced it has entered into a licensing agreement with Australia’s Institution for Glycomics at Griffith University, focused on the latter’s first-in-class parainfluenza drug.
The Center for Drug Evaluation (CDE)’s website indicated that a clinical trial filing is currently under review in relation to pan fibroblast growth factor receptor (FGFR) inhibitor erdafitinib (Balversa), filed by Johnson & Johnson's China-based subsidiary Xian Janssen.
Analytics Snapshot


Analytics Snapshot